uniQure (NASDAQ:QURE) Director Madhavan Balachandran Sells 1,993 Shares of Stock

uniQure N.V. (NASDAQ:QURE) Director Madhavan Balachandran sold 1,993 shares of the firm’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $27.06, for a total value of $53,930.58. Following the transaction, the director owned 43,254 shares in the company, valued at approximately $1,170,453.24. This trade represents a 4.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

uniQure Price Performance

Shares of NASDAQ:QURE opened at $27.57 on Friday. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The stock’s fifty day simple moving average is $22.52 and its two-hundred day simple moving average is $21.80. uniQure N.V. has a 1-year low of $8.73 and a 1-year high of $71.50. The stock has a market cap of $1.74 billion, a PE ratio of -7.92 and a beta of 0.98.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The business had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.21 million. As a group, analysts forecast that uniQure N.V. will post -3.64 EPS for the current fiscal year.

Institutional Investors Weigh In On uniQure

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Militia Capital Management LLC bought a new stake in shares of uniQure during the first quarter valued at about $1,540,000. Flax Pond Capital LLC increased its position in shares of uniQure by 3.8% during the first quarter. Flax Pond Capital LLC now owns 152,031 shares of the biotechnology company’s stock valued at $2,486,000 after buying an additional 5,533 shares during the period. Stempoint Capital LP increased its position in shares of uniQure by 79.5% during the first quarter. Stempoint Capital LP now owns 78,066 shares of the biotechnology company’s stock valued at $1,276,000 after buying an additional 34,581 shares during the period. Irenic Capital Management LP purchased a new position in shares of uniQure during the first quarter worth about $1,635,000. Finally, Readystate Asset Management LP grew its holdings in shares of uniQure by 39.6% during the first quarter. Readystate Asset Management LP now owns 504,702 shares of the biotechnology company’s stock worth $8,252,000 after purchasing an additional 143,142 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors.

Key uniQure News

Here are the key news stories impacting uniQure this week:

• Negative Sentiment: A cluster of insiders sold shares in recent filings, including directors Robert Gut, Madhavan Balachandran, Rachelle Suzanne Jacques, Jack Kaye, Leonard E. Post, Jeremy P. Springhorn, and David D. Meek, along with insider Kylie O’keefe. The transactions totaled a meaningful reduction in ownership across the group, increasing focus on insider confidence. Article: UniQure Rocked by Wave of High-Level Insider Stock Sales
• Neutral Sentiment: Several of the sales were made under pre-arranged Rule 10b5-1 trading plans, which can lessen the bearish signal because the trades may have been scheduled in advance rather than reflecting a sudden change in outlook.
• Neutral Sentiment: The stock has already been trending above its 50-day and 200-day moving averages, so some of the selling may simply reflect profit-taking after a strong move rather than a deterioration in the company’s fundamentals.

Wall Street Analyst Weigh In

QURE has been the topic of several recent analyst reports. Royal Bank Of Canada upgraded uniQure from a “sector perform” rating to an “outperform” rating and raised their price objective for the company from $11.00 to $35.00 in a research note on Monday, March 9th. Mizuho raised uniQure from a “neutral” rating to an “outperform” rating and upped their price target for the company from $12.00 to $35.00 in a research report on Wednesday, March 11th. Wall Street Zen upgraded uniQure from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Barclays lowered their price objective on uniQure from $31.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Monday, March 23rd. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $9.00 price objective (down from $55.00) on shares of uniQure in a research note on Monday, March 2nd. Ten equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $42.83.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.